Polarityte (PTE) Given a $65.00 Price Target by Cantor Fitzgerald Analysts

Polarityte (NASDAQ:PTE) received a $65.00 target price from research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 438.08% from the stock’s previous close.

Several other equities research analysts also recently issued reports on the stock. Piper Jaffray Companies set a $30.00 target price on shares of Polarityte and gave the company a “buy” rating in a research note on Monday. Zacks Investment Research downgraded shares of Polarityte from a “hold” rating to a “sell” rating in a research note on Tuesday. Northland Securities reiterated a “buy” rating and issued a $50.00 target price on shares of Polarityte in a research note on Monday. ValuEngine downgraded shares of Polarityte from a “buy” rating to a “hold” rating in a research note on Tuesday, February 5th. Finally, Oppenheimer assumed coverage on shares of Polarityte in a research note on Tuesday, January 29th. They issued an “outperform” rating and a $30.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Polarityte presently has a consensus rating of “Hold” and a consensus target price of $36.00.

Polarityte stock opened at $12.08 on Tuesday. Polarityte has a one year low of $11.54 and a one year high of $41.22. The stock has a market cap of $282.58 million, a PE ratio of -2.49 and a beta of 1.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 13.80 and a quick ratio of 13.76.

Polarityte (NASDAQ:PTE) last issued its earnings results on Monday, January 14th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.02) by $0.06. Polarityte had a negative net margin of 4,259.44% and a negative return on equity of 258.52%. The business had revenue of $1.13 million during the quarter, compared to the consensus estimate of $0.80 million. On average, sell-side analysts expect that Polarityte will post -4.11 earnings per share for the current fiscal year.

Polarityte Company Profile

PolarityTE, Inc, a biotechnology and regenerative biomaterials company, focuses on discovering, designing, and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services.

Read More: Quiet Period

Analyst Recommendations for Polarityte (NASDAQ:PTE)

Receive News & Ratings for Polarityte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polarityte and related companies with MarketBeat.com's FREE daily email newsletter.